Revolutionary hemostatic gel for veterinary
surgeons available in U.K. and across Europe through Veterinary Instrumentation and
distribution partners
NEW
YORK, May 20, 2024 /PRNewswire/ -- Cresilon Inc.
("Cresilon"), a Brooklyn-based
biotechnology company focused on hemostatic medical device
technologies, today announced it has entered into a distribution
agreement for its revolutionary hemostatic gel,
VETIGEL®, to be sold directly to veterinary surgeons in
the U.K. and throughout Europe
through Veterinary Instrumentation (Vi), a leading supplier of
professional products to support veterinarians in maintaining
animal welfare during surgery.
Based in the U.K., Vi is part of the Covetrus animal health
family of worldwide businesses. Cresilon's VETIGEL, a plant-based
hemostatic gel that instantly stops and controls bleeding, is
available online for U.K. veterinary surgeons through Vi's
extensive portfolio of surgical and orthopedic instrumentation,
joint surgery, and fracture fixation products.
In addition to the U.K., VETIGEL will be marketed and
distributed to veterinary surgeons throughout Europe and many other countries through Vi's
extensive global distribution network. Cresilon's Scientific
Services Veterinarian and Fellow of the Royal College of Veterinary
Surgeons (FRCVS), Dr. Neil Smith,
will be providing online training on VETIGEL to all Vi distribution
partners in June.
"Our partnership with Veterinary Instrumentation will help us
provide more veterinary surgeons with a revolutionary hemostatic
gel that significantly improves the standard of care for pets and
animals," said Matt Lewis, Vice
President of Sales at Cresilon. "VETIGEL has been used by thousands
of veterinarians thus far and helps veterinary clinics and animal
hospitals save time, reduce operating costs, and improve patient
outcomes."
Since the product's debut in 2021, veterinary surgeons across
North America, Europe, and Asia have increasingly used VETIGEL as the
fastest and most effective hemostatic agent when treating animals
for traumatic wounds and routine and complex surgical procedures,
including dental extractions, liver biopsies, tumor and mass
removals, cleft palate repairs, and amputations. To date, the
plant-based hemostatic gel for veterinary surgeons has been used in
more than 50,000 surgical procedures worldwide.
VETIGEL offers veterinary surgeons a safe and efficient way to
control animal bleeding across multiple types of bleeds and a wide
range of surgical procedures. The veterinary hemostatic agent is
made of two plant-based polysaccharides that form an instant
mechanical barrier to stop bleeding on contact. Once the bleeding
is controlled, VETIGEL can be easily removed without disturbing the
underlying clot or left in the body to resorb.
The plant-based hemostatic gel is supplied in a pre-filled
syringe, is easy-to-use, and requires no preparation or special
storage conditions. For more information about VETIGEL, visit
www.vetigel.com.
About Cresilon
Cresilon® is a Brooklyn-based biotechnology company that
develops, manufactures, and markets hemostatic medical devices
utilizing the company's proprietary hydrogel technology. The
company's plant-based technology has revolutionized the current
standard by stopping bleeding in seconds. The company's current and
future product lines target veterinary, human trauma, and human
surgical applications. Cresilon's mission is to save lives. For
more information about Cresilon, which was named to Fast Company's
annual list of the World's Most Innovative Companies of 2024,
ranking No. 1 in the medical devices category, visit
www.cresilon.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cresilon-announces-international-distribution-agreement-for-vetigel-with-covetrus-302149473.html
SOURCE Cresilon